GTAM
VRTX icon

Global Trust Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Global Trust Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Sell
262
-10
-4% -$4.43K 0.04% 172
2026
Q1 		$121K Sell
272
-158
-37% -$73.7K 0.05% 177
2025
Q4 		$195K Sell
430
-156
-27% -$67.2K 0.08% 141
2025
Q3 		$230K Buy
586
+18
+3% +$7.52K 0.1% 156
2025
Q2 		$253K Sell
568
-65
-10% -$30K 0.14% 136
2025
Q1 		$307K Sell
633
-14
-2% -$6.52K 0.19% 114
2024
Q4 		$261K Sell
647
-390
-38% -$181K 0.1% 148
2024
Q3 		$482K Buy
1,037
+220
+27% +$106K 0.18% 111
2024
Q2 		$383K Sell
817
-15
-2% -$6.51K 0.15% 119
2024
Q1 		$348K Sell
832
-830
-50% -$351K 0.14% 128
2023
Q4 		$676K Sell
1,662
-85
-5% -$31.4K 0.3% 79
2023
Q3 		$608K Sell
1,747
-75
-4% -$26.2K 0.29% 81
2023
Q2 		$641K Sell
1,822
-15
-0.8% -$5.05K 0.29% 79
2023
Q1 		$579K Buy
1,837
+100
+6% +$30K 0.28% 82
2022
Q4 		$502K Sell
1,737
-315
-15% -$96K 0.25% 88
2022
Q3 		$594K Buy
2,052
+50
+2% +$14.4K 0.31% 75
2022
Q2 		$564K Sell
2,002
-1,050
-34% -$281K 0.28% 88
2022
Q1 		$796K Buy
3,052
+2,868
+1,559% +$681K 0.33% 68
2021
Q4 		$40K Buy
184
+115
+167% +$22.4K 0.02% 271
2021
Q3 		$13K Hold
69
– – 0.01% 309
2021
Q2 		$14K Buy
+69
New +$14.4K 0.01% 306
2020
Q3 		– Sell
-1,275
Closed -$370K – 396
2020
Q2 		$370K Sell
1,275
-875
-41% -$237K 0.26% 95
2020
Q1 		$499K Buy
+2,150
New +$493K 0.39% 74
2019
Q1 		– Sell
-63
Closed -$10K – 449
2018
Q4 		$10K Hold
63
– – 0.01% 282
2018
Q3 		$12K Hold
63
– – 0.01% 307
2018
Q2 		$11K Hold
63
– – 0.01% 301
2018
Q1 		$10K Hold
63
– – 0.01% 297
2017
Q4 		$9K Buy
+63
New +$9.33K 0.01% 311

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Global Trust Asset Management's VRTX Position: Q2 2026 in Review

Global Trust Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 3.7% in Q2 2026, selling an estimated $4.43K and leaving 262 shares worth $130K. The position accounts for 0.04% of the portfolio, ranked #172.

Global Trust Asset Management first reported a position in VRTX in Q4 2017 and has held it in 28 quarters since. The position peaked at $796K in Q1 2022. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Global Trust Asset Management held 262 shares of Vertex Pharmaceuticals worth $130K as of Q2 2026.
  • Global Trust Asset Management sold 10 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.43K.
  • Vertex Pharmaceuticals made up 0.04% of Global Trust Asset Management's portfolio in Q2 2026, its #172 holding.
  • Global Trust Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 28 quarters since.
  • Global Trust Asset Management's Vertex Pharmaceuticals position peaked at $796K in Q1 2022.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Global Trust Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.